 primari prophylaxi pneumocysti carinii pneumonia hiv-infect peopl count cost-effect analysi decision-analyt model effect cost dapson trimethoprim-sulfamethoxazol aerosol pentamidin initi prophylaxi pneumocysti carinii pneumonia human immunodefici virus-infect peopl prior symptom aid strategi life expect prophylaxi annual per-person cost dapson trimethoprim-sulfamethoxazol aerosol pentamidin cost differ strategi dapson cost effect increment cost-effect ratio life year prophylaxi aerosol pentamidin cost effect increment cost effect ratio depend estim qualiti life efficaci toxic complianc avail data initi prophylaxi dapson trimethoprim-sulfamethoxazol cost effect peopl prophylaxi trimethoprim-sulfamethoxazol dapson crossov pentamidin oral therapi year